Navigation Links
FDA Approves Latuda to Treat Schizophrenia in Adults

SILVER SPRING, Md., Oct. 28 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia.



Schizophrenia affects about 1 percent of the U.S. population, ages 18 years and older, in a given year. The most prominent symptoms include hallucinations, delusions, disordered thinking and behavior, and suspiciousness. Hearing voices that other people don't hear is the most common type of hallucination. These experiences can make people with the disorder fearful and withdrawn.

"Schizophrenia can be a devastating illness requiring lifelong treatment," said Thomas Laughren, M.D., director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research. "Some patients do not respond well to certain types of drug therapy, so it is important to have multiple treatment options available."

Latuda is included in the atypical antipsychotic class of drugs. All atypical antipsychotics contain a boxed warning alerting prescribers to an increased risk of death associated with off-label use of these drugs to treat behavioral problems in older people with dementia-related psychosis. No drug in this class is approved to treat patients with dementia-related psychosis.

Four six-week controlled studies of adults with schizophrenia demonstrated the effectiveness and safety of Latuda. In the trials, patients treated with Latuda had fewer symptoms of schizophrenia than those taking an inactive pill (placebo).  

The most common adverse reactions reported by those in clinical trials were drowsiness, feelings of restlessness and the urge to move (akathisia), nausea, movement abnormalities such as tremors, slow movement, or muscle stiffness (Parkinsonism), and agitation.

Latuda is manufactured by Sunovion Pharmaceuticals Inc. of Fort Lee, N.J.

For information:

National Institute of Mental Health: Schizophrenia

Approved Drugs: Questions and Answers

Media Inquiries: Sandy Walsh, 301-796-4669;

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Additional Medical Indication for Sprycel
2. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
3. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
4. FDA Approves Botox to Treat Chronic Migraine
5. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
6. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
7. FDA Approves Combination Contraceptive Containing a Folate
8. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
9. FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
10. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
11. FDA Approves Pediatric Use of Chemical Poisoning Treatment
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 NHS Supply ... 20 TrueBeam™ machines from Varian Medical Systems (NYSE: ... program to replace older machines and institute modern ... UK,s public hospitals. The order, placed in September, ... licenses for Varian,s RapidArc® and Eclipse™ software systems.    ...
(Date:11/30/2015)... , Nov. 30, 2015  Hanger, Inc. (NYSE: ... restatement of the terms of its previously announced consent ... to its $200,000,000 aggregate principal amount 7⅛% Senior Notes ... (i) the consent fees payable pursuant to the Consent ... Notes and (iii) the expiration date of the Consent ...
(Date:11/30/2015)... , Nov. 30, 2015  Precision Image ... services, is pleased to announce a dramatic expansion ... imaging services. Building on its ISO-9001:2008 certification for ... implemented comprehensive Core Lab protocols and procedures. This ... of research activities.  Their Core Lab services include ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... Center is one of a select few plastic surgeons in the New York ... removal. , SculpSure™ is the world’s first heat-induced laser treatment for fat loss ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... TransPack Volume ... X . Choose from scrolling web-styled transitions to wipes with blur & drop ... direction and more. Seamlessly transition from one clip to the next with TransPack's ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their strategic partnership at the Radiological Society of North America (RSNA) 2015 ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... In 2016, expected coding changes are likely to include new codes for spine ... not easy to understand the effects of code changes in musculoskeletal, radiology and ...
(Date:11/30/2015)... ... 30, 2015 , ... CTI Group (Holdings) Inc. (OTC:CTIG), a ... communication analytics, announced today that their Proteus® VoIP QMS solution now supports Skype ... Proteus® VoIP QMS (Quality Management System) does this by collecting the ...
Breaking Medicine News(10 mins):